Prevalence and outcomes of intermediate saphenous vein graft lesions: Findings from the stenting of saphenous vein grafts randomized-controlled trial

Abdul Rahman R Abdel-Karim, Monica Da Silva, Christopher Lichtenwalter, James A de Lemos, Owen Obel, Tayo A Addo, Michele Roesle, Donald Haagen, Bavana Venkata Rangan, Lorenza Makke, Omar M. Jeroudi, Deepa Raghunathan, Bilal Saeed, Joseph K. Bissett, Rajesh Sachdeva, Vassilios V. Voudris, Panagiotis Karyofillis, Biswajit Kar, James Rossen, Panayotis FasseasPeter Berger, Subhash Banerjee, Emmanouil S Brilakis

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background We sought to examine the prevalence and progression rate of intermediate saphenous vein graft (SVG) lesions in the Stenting Of Saphenous vein grafts (SOS) trial. Methods The baseline and follow-up angiograms of 80 patients participating in the SOS trial were analyzed to determine the prevalence of intermediate (30-60% angiographic diameter stenosis) SVG lesions and their progression rate. Results At least one intermediate SVG lesion was present in 31 of 143 (22%) SVGs in 27 of 80 (34%) patients. Most intermediate lesions were present in the SOS stented SVGs (20 grafts in 19 patients). During a median follow-up of 35 months, angiographic follow-up was available for 28 grafts in 25 patients. Progression (defined as percent diameter stenosis ≥ 70% but < 100% at follow-up angiography) was seen in 11 of 28 SVGs (39%) in 11 of 25 patients (44%). Progression rate at 12, 24 and 36 months was 28% and 47% and 84%, respectively. Seven of 11 patients (64%) with intermediate SVG lesion progression presented with an acute coronary syndrome and 8 (73%) underwent PCI. Four of the 28 grafts with intermediate lesions at baseline were 100% occluded at follow-up; all of those SVGs had received a stent in another location in the SVG as part of the SOS trial. Conclusions Intermediate SVG lesions are common in patients undergoing SVG stenting, have high rates of progression and frequently present with an acute coronary syndrome. Further study of pharmacologic and mechanical treatments to prevent progression of these lesions is needed.

Original languageEnglish (US)
Pages (from-to)2468-2473
Number of pages6
JournalInternational Journal of Cardiology
Volume168
Issue number3
DOIs
StatePublished - Oct 3 2013

Fingerprint

Saphenous Vein
Randomized Controlled Trials
Transplants
Acute Coronary Syndrome
Angiography
Pathologic Constriction
Stents

Keywords

  • Percutaneous Coronary Interventions
  • Saphenous vein grafts
  • Stents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Prevalence and outcomes of intermediate saphenous vein graft lesions : Findings from the stenting of saphenous vein grafts randomized-controlled trial. / Abdel-Karim, Abdul Rahman R; Da Silva, Monica; Lichtenwalter, Christopher; de Lemos, James A; Obel, Owen; Addo, Tayo A; Roesle, Michele; Haagen, Donald; Rangan, Bavana Venkata; Makke, Lorenza; Jeroudi, Omar M.; Raghunathan, Deepa; Saeed, Bilal; Bissett, Joseph K.; Sachdeva, Rajesh; Voudris, Vassilios V.; Karyofillis, Panagiotis; Kar, Biswajit; Rossen, James; Fasseas, Panayotis; Berger, Peter; Banerjee, Subhash; Brilakis, Emmanouil S.

In: International Journal of Cardiology, Vol. 168, No. 3, 03.10.2013, p. 2468-2473.

Research output: Contribution to journalArticle

Abdel-Karim, ARR, Da Silva, M, Lichtenwalter, C, de Lemos, JA, Obel, O, Addo, TA, Roesle, M, Haagen, D, Rangan, BV, Makke, L, Jeroudi, OM, Raghunathan, D, Saeed, B, Bissett, JK, Sachdeva, R, Voudris, VV, Karyofillis, P, Kar, B, Rossen, J, Fasseas, P, Berger, P, Banerjee, S & Brilakis, ES 2013, 'Prevalence and outcomes of intermediate saphenous vein graft lesions: Findings from the stenting of saphenous vein grafts randomized-controlled trial', International Journal of Cardiology, vol. 168, no. 3, pp. 2468-2473. https://doi.org/10.1016/j.ijcard.2013.03.006
Abdel-Karim, Abdul Rahman R ; Da Silva, Monica ; Lichtenwalter, Christopher ; de Lemos, James A ; Obel, Owen ; Addo, Tayo A ; Roesle, Michele ; Haagen, Donald ; Rangan, Bavana Venkata ; Makke, Lorenza ; Jeroudi, Omar M. ; Raghunathan, Deepa ; Saeed, Bilal ; Bissett, Joseph K. ; Sachdeva, Rajesh ; Voudris, Vassilios V. ; Karyofillis, Panagiotis ; Kar, Biswajit ; Rossen, James ; Fasseas, Panayotis ; Berger, Peter ; Banerjee, Subhash ; Brilakis, Emmanouil S. / Prevalence and outcomes of intermediate saphenous vein graft lesions : Findings from the stenting of saphenous vein grafts randomized-controlled trial. In: International Journal of Cardiology. 2013 ; Vol. 168, No. 3. pp. 2468-2473.
@article{eb51a84d883043c5bfc4838cbd1e8f57,
title = "Prevalence and outcomes of intermediate saphenous vein graft lesions: Findings from the stenting of saphenous vein grafts randomized-controlled trial",
abstract = "Background We sought to examine the prevalence and progression rate of intermediate saphenous vein graft (SVG) lesions in the Stenting Of Saphenous vein grafts (SOS) trial. Methods The baseline and follow-up angiograms of 80 patients participating in the SOS trial were analyzed to determine the prevalence of intermediate (30-60{\%} angiographic diameter stenosis) SVG lesions and their progression rate. Results At least one intermediate SVG lesion was present in 31 of 143 (22{\%}) SVGs in 27 of 80 (34{\%}) patients. Most intermediate lesions were present in the SOS stented SVGs (20 grafts in 19 patients). During a median follow-up of 35 months, angiographic follow-up was available for 28 grafts in 25 patients. Progression (defined as percent diameter stenosis ≥ 70{\%} but < 100{\%} at follow-up angiography) was seen in 11 of 28 SVGs (39{\%}) in 11 of 25 patients (44{\%}). Progression rate at 12, 24 and 36 months was 28{\%} and 47{\%} and 84{\%}, respectively. Seven of 11 patients (64{\%}) with intermediate SVG lesion progression presented with an acute coronary syndrome and 8 (73{\%}) underwent PCI. Four of the 28 grafts with intermediate lesions at baseline were 100{\%} occluded at follow-up; all of those SVGs had received a stent in another location in the SVG as part of the SOS trial. Conclusions Intermediate SVG lesions are common in patients undergoing SVG stenting, have high rates of progression and frequently present with an acute coronary syndrome. Further study of pharmacologic and mechanical treatments to prevent progression of these lesions is needed.",
keywords = "Percutaneous Coronary Interventions, Saphenous vein grafts, Stents",
author = "Abdel-Karim, {Abdul Rahman R} and {Da Silva}, Monica and Christopher Lichtenwalter and {de Lemos}, {James A} and Owen Obel and Addo, {Tayo A} and Michele Roesle and Donald Haagen and Rangan, {Bavana Venkata} and Lorenza Makke and Jeroudi, {Omar M.} and Deepa Raghunathan and Bilal Saeed and Bissett, {Joseph K.} and Rajesh Sachdeva and Voudris, {Vassilios V.} and Panagiotis Karyofillis and Biswajit Kar and James Rossen and Panayotis Fasseas and Peter Berger and Subhash Banerjee and Brilakis, {Emmanouil S}",
year = "2013",
month = "10",
day = "3",
doi = "10.1016/j.ijcard.2013.03.006",
language = "English (US)",
volume = "168",
pages = "2468--2473",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Prevalence and outcomes of intermediate saphenous vein graft lesions

T2 - Findings from the stenting of saphenous vein grafts randomized-controlled trial

AU - Abdel-Karim, Abdul Rahman R

AU - Da Silva, Monica

AU - Lichtenwalter, Christopher

AU - de Lemos, James A

AU - Obel, Owen

AU - Addo, Tayo A

AU - Roesle, Michele

AU - Haagen, Donald

AU - Rangan, Bavana Venkata

AU - Makke, Lorenza

AU - Jeroudi, Omar M.

AU - Raghunathan, Deepa

AU - Saeed, Bilal

AU - Bissett, Joseph K.

AU - Sachdeva, Rajesh

AU - Voudris, Vassilios V.

AU - Karyofillis, Panagiotis

AU - Kar, Biswajit

AU - Rossen, James

AU - Fasseas, Panayotis

AU - Berger, Peter

AU - Banerjee, Subhash

AU - Brilakis, Emmanouil S

PY - 2013/10/3

Y1 - 2013/10/3

N2 - Background We sought to examine the prevalence and progression rate of intermediate saphenous vein graft (SVG) lesions in the Stenting Of Saphenous vein grafts (SOS) trial. Methods The baseline and follow-up angiograms of 80 patients participating in the SOS trial were analyzed to determine the prevalence of intermediate (30-60% angiographic diameter stenosis) SVG lesions and their progression rate. Results At least one intermediate SVG lesion was present in 31 of 143 (22%) SVGs in 27 of 80 (34%) patients. Most intermediate lesions were present in the SOS stented SVGs (20 grafts in 19 patients). During a median follow-up of 35 months, angiographic follow-up was available for 28 grafts in 25 patients. Progression (defined as percent diameter stenosis ≥ 70% but < 100% at follow-up angiography) was seen in 11 of 28 SVGs (39%) in 11 of 25 patients (44%). Progression rate at 12, 24 and 36 months was 28% and 47% and 84%, respectively. Seven of 11 patients (64%) with intermediate SVG lesion progression presented with an acute coronary syndrome and 8 (73%) underwent PCI. Four of the 28 grafts with intermediate lesions at baseline were 100% occluded at follow-up; all of those SVGs had received a stent in another location in the SVG as part of the SOS trial. Conclusions Intermediate SVG lesions are common in patients undergoing SVG stenting, have high rates of progression and frequently present with an acute coronary syndrome. Further study of pharmacologic and mechanical treatments to prevent progression of these lesions is needed.

AB - Background We sought to examine the prevalence and progression rate of intermediate saphenous vein graft (SVG) lesions in the Stenting Of Saphenous vein grafts (SOS) trial. Methods The baseline and follow-up angiograms of 80 patients participating in the SOS trial were analyzed to determine the prevalence of intermediate (30-60% angiographic diameter stenosis) SVG lesions and their progression rate. Results At least one intermediate SVG lesion was present in 31 of 143 (22%) SVGs in 27 of 80 (34%) patients. Most intermediate lesions were present in the SOS stented SVGs (20 grafts in 19 patients). During a median follow-up of 35 months, angiographic follow-up was available for 28 grafts in 25 patients. Progression (defined as percent diameter stenosis ≥ 70% but < 100% at follow-up angiography) was seen in 11 of 28 SVGs (39%) in 11 of 25 patients (44%). Progression rate at 12, 24 and 36 months was 28% and 47% and 84%, respectively. Seven of 11 patients (64%) with intermediate SVG lesion progression presented with an acute coronary syndrome and 8 (73%) underwent PCI. Four of the 28 grafts with intermediate lesions at baseline were 100% occluded at follow-up; all of those SVGs had received a stent in another location in the SVG as part of the SOS trial. Conclusions Intermediate SVG lesions are common in patients undergoing SVG stenting, have high rates of progression and frequently present with an acute coronary syndrome. Further study of pharmacologic and mechanical treatments to prevent progression of these lesions is needed.

KW - Percutaneous Coronary Interventions

KW - Saphenous vein grafts

KW - Stents

UR - http://www.scopus.com/inward/record.url?scp=84885653004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885653004&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2013.03.006

DO - 10.1016/j.ijcard.2013.03.006

M3 - Article

C2 - 23561918

AN - SCOPUS:84885653004

VL - 168

SP - 2468

EP - 2473

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 3

ER -